Practice Note: How Bio-Rad’s old FCPA settlement became a ‘risk factor’
You would expect investors to be pleased and optimist when their company resolves an FCPA case by paying relatively moderate penalties and landing a DOJ non-prosecution agreement.
Good news, the dark cloud is gone.… Continue Reading